Upcoming updates
for 2026-2027
Ophthalmologic Effects of Antidepressants: A Clinical Guide
Cardiac Side Effects of Psychiatric Medications
Treatment-Resistant Obsessive-Compulsive Disorder (Update) – Interview
Lamotrigine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 91
Management of Psychotropic-Induced Sexual Dysfunction – Interview
Pharmacotherapy of Borderline Personality Disorder (Second Edition)
Valproate Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 92
Lithium Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Pharmacotherapy for Cannabis Use Disorder
Pharmacotherapy of treatment-resistant depression – Interview
Quick Take Vol. 93
Buspirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Switching Antipsychotics in Clinical Practice 2026 update
Bipolar Disorder Pharmacotherapy – Interview
Atomoxetine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 94
Psychopharmacology of Autism
Psychotropic-Induced Movement Disorders and Cognitive Side Effects – Interview
Methylphenidate Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 95
Pharmacotherapy Bipolar Depression: Strategies for Everyday Management – Interview
Drug-Drug Interactions in Psychopharmacology.
Amphetamines Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 96
ADHD Medications: A Comprehensive Formulations Guide
Antidepressant Withdrawal Effects and Safe Deprescribing – Interview
Pharmacotherapy of Substance Use Disorders in Pregnancy
Quick Take Vol. 97
Brexpiprazole Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Addiction Psychopharmacology in Patients with Medical Comorbidities – Interview
Bipolar Disorder in the Perinatal Period (2nd Edition)
Cariprazine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Psychopharmacology of Weight Gain and Obesity
Lumateperone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
CME Information
Physicians – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nursing professionals – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour.
All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.
This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.
Physician assistants – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physicians outside the United States – CME Accreditation Statement
AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.
Self Assessment for MOC – Accreditation Statement
- Psychopharmacology Institute Self-Assessment Program 2025
Dates: April 1, 2025 – April 1, 2028
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2024
Dates: April 1, 2024 – April 1, 2027
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.